A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 152,328 shares of CHRS stock, worth $240,678. This represents 0.0% of its overall portfolio holdings.

Number of Shares
152,328
Holding current value
$240,678
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$2.02 - $3.14 $307,702 - $478,309
152,328 New
152,328 $364,000
Q3 2022

Nov 14, 2022

SELL
$7.17 - $13.87 $1.09 Million - $2.12 Million
-152,700 Reduced 74.31%
52,800 $507,000
Q2 2022

Aug 12, 2022

BUY
$5.86 - $13.23 $242,604 - $547,722
41,400 Added 25.23%
205,500 $1.49 Million
Q1 2022

May 13, 2022

BUY
$10.92 - $16.41 $1.18 Million - $1.78 Million
108,300 Added 194.09%
164,100 $2.12 Million
Q4 2021

Feb 11, 2022

BUY
$15.81 - $18.99 $882,198 - $1.06 Million
55,800 New
55,800 $891,000
Q2 2021

Aug 13, 2021

SELL
$12.95 - $15.41 $2.99 Million - $3.56 Million
-230,700 Closed
0 $0
Q1 2021

May 13, 2021

SELL
$14.42 - $21.39 $439,810 - $652,395
-30,500 Reduced 11.68%
230,700 $3.37 Million
Q4 2020

Feb 10, 2021

BUY
$16.56 - $18.94 $2.97 Million - $3.4 Million
179,300 Added 218.93%
261,200 $4.54 Million
Q3 2020

Nov 13, 2020

SELL
$17.41 - $19.89 $5.64 Million - $6.45 Million
-324,200 Reduced 79.83%
81,900 $1.5 Million
Q2 2020

Aug 13, 2020

BUY
$14.43 - $19.16 $4.71 Million - $6.25 Million
326,200 Added 408.26%
406,100 $7.25 Million
Q1 2020

May 14, 2020

SELL
$11.67 - $22.53 $561,327 - $1.08 Million
-48,100 Reduced 37.58%
79,900 $1.3 Million
Q4 2019

Feb 13, 2020

BUY
$16.33 - $21.37 $2.09 Million - $2.74 Million
128,000 New
128,000 $2.31 Million

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $123M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.